The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of a new subcutaneous formulation of Sanofi’s Sarclisa and four additional new drugs, according to its latest opinions. The CHMP recommendations are a key step toward broader European authorization and label expansion. The Sanofi change matters for patient-facing administration, as subcutaneous options can reduce infusion-center dependency and potentially improve convenience for some myeloma patients. Alongside other recommended drugs, the move underscores CHMP’s continued focus on refining routes of administration and expanding the therapeutic toolkit. The final outcome depends on subsequent steps in the centralized approval process, but the CHMP recommendation provides an actionable signal for healthcare systems planning uptake.